Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab in elderly DLBCL patients. The monotherapy arm (EPCORE DLBCL-3) showed 67% overall response rate and 58% complete response rate, while the combination with R-mini-CHOP (EPCORE NHL-2) demonstrated 93% overall response rate and 86% complete response rate with durable remissions and sustained MRD negativity.

06/13/2026, 12:45 PM • GlobeNewswire

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab A/S announced the disclosure of share transactions made by managerial employees and their closely associated persons in accordance with EU market abuse regulations. The company also announced a capital increase of 2,346 shares resulting from employee warrant exercises.

05/29/2026, 4:35 PM • GlobeNewswire

Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development Platforms

The bispecific antibody drug conjugate (BsADC) market is expected to reach over $2 billion by 2030, with the first BsADC approval anticipated by 2028. Over 150 clinical trials are underway globally, with China leading development efforts. Key candidates like Izalontamab brengitecan and JSKN003 are showing positive clinical results in cancer treatment, positioning BsADCs as the next generation of targeted therapies.

04/21/2026, 4:49 AM • GlobeNewswire

Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook

The bispecific antibodies market is projected to reach over $60 billion by 2031, growing from $16 billion in 2025. With 18 approved bispecific antibodies and over 550 clinical trials underway, the market is transitioning toward commercial maturity driven by clinical progress in cancer, autoimmune, and inflammatory therapies. Major pharmaceutical players and emerging biotech companies are actively expanding their pipelines through strategic collaborations and technological innovation.

04/21/2026, 4:34 AM • GlobeNewswire

Genmab A/S Share Capital Reduction

Genmab A/S has completed a share capital reduction by canceling 1.9 million treasury shares, reducing total share capital from DKK 64.25 million to DKK 62.35 million. The reduction was approved at the Annual General Meeting on March 19, 2026, and registered with Danish authorities on April 17, 2026. Nasdaq systems will be updated by April 21, 2026.

04/17/2026, 10:56 AM • GlobeNewswire

Major Shareholder Announcement

Orbis Investment Management Limited has disclosed a 4.99% stake in Genmab A/S as of March 27, 2026, controlling 3,205,763 shares. The announcement was made under Danish Capital Markets Act requirements. Genmab also held its Annual General Meeting on March 19, 2026, where the 2025 Annual Report was approved and discharge was given to the Board of Directors and Executive Management.

03/30/2026, 12:00 PM • GlobeNewswire

Correction to Company Announcement No. 13 of March 2, 2026

Genmab A/S issued a correction to a previous company announcement regarding managerial employee share transactions, correcting the reported share price from DKK 0.00 to DKK 1,867.50. The announcement discloses vesting and net settlement of restricted stock units granted to executives Jan van de Winkel and Anthony Pagano in February 2023.

03/02/2026, 4:53 PM • GlobeNewswire

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab A/S announced the vesting and net settlement of restricted stock units (RSUs) granted to executives Jan van de Winkel and Anthony Pagano on February 24, 2023, as part of deferred annual bonus achievement. The disclosure is made in accordance with EU market abuse regulations requiring transparency of insider trading activities.

03/02/2026, 2:58 PM • GlobeNewswire

Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica

The global targeted cancer therapy market is projected to grow from USD 90.89 billion in 2025 to USD 175.48 billion by 2035 at a CAGR of 6.80%. Growth is driven by antibody-drug conjugates (ADCs), KRAS inhibitors, bispecific antibodies, and regulatory productivity. Monoclonal antibodies capture 43% revenue share, lung cancer represents 32% of the market, and hospitals account for 58% of end-user share. North America dominates with 39% market share.

02/03/2026, 1:56 AM • GlobeNewswire

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab announced topline results from the Phase 3 EPCORE DLBCL-1 trial showing epcoritamab demonstrated improvement in progression-free survival (HR: 0.74) in relapsed/refractory DLBCL patients. However, overall survival did not reach statistical significance (HR: 0.96). The company will engage regulatory authorities to discuss next steps, with additional Phase 3 trial data expected in 2026.

01/16/2026, 1:30 PM • GlobeNewswire

[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expansion initiatives across North America, Europe, and Asia-Pacific regions.

01/14/2026, 3:30 AM • GlobeNewswire

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Genmab has successfully acquired 94.2% of Merus N.V.'s outstanding shares at $97 per share, adding petosemtamab to its portfolio and positioning itself for potential billion-dollar revenue by 2029.

12/12/2025, 1:35 AM • GlobeNewswire

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Genmab will host a virtual R&D Update and ASH Data Review Meeting on December 11, 2025, presenting recent research and development insights in antibody therapeutics for cancer and serious diseases.

12/11/2025, 2:00 AM • GlobeNewswire

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Genmab presented promising clinical trial results for epcoritamab, a T-cell engaging bispecific antibody, showing potential efficacy in treating Richter transformation across different treatment settings with encouraging response and survival rates.

12/08/2025, 4:30 PM • GlobeNewswire

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Genmab announced positive Phase 3 trial results for EPKINLY, demonstrating significant clinical benefits in treating relapsed or refractory follicular lymphoma when combined with rituximab and lenalidomide, reducing disease progression risk by 79% and achieving a 95% overall response rate.

12/07/2025, 7:50 AM • GlobeNewswire